| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 9, 2024Responses of 1,000 people with chronic pain in the UK reveal the far-reaching burden of chronic pain on mental health, with many feeling misunderstood
HEMEL HEMPSTEAD, United Kingdom – 9 September, 2024 – A new survey highlights the profound impact chronic pain has on the lives of people living in the UK, often severely affecting their...
Aug 27, 2024Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...
Jun 20, 2024Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditionsHEMEL HEMPSTEAD, United Kingdom – 20 June 2024 – Boston Scientific Corporation (NYSE: BSX) has obtained CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology,...
-
Jan 8, 2024Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily...
Dec 12, 2023New virtual power purchase agreement helps to advance the company’s decarbonisation goals on its path to net zeroMADRID, SPAIN, 12 December 2023 – Boston Scientific Corporation (NYSE: BSX) has activated its first European virtual power purchase agreement (VPPA) with leading renewable energy developer and solutions provider BayWa r.e., helping the company make progress on its decarbonisation targets.
-
Sep 5, 2023Research conducted in the United Kingdom for pain awareness month points to a gender difference in the experience of chronic pain, pursuing pain relief and the feeling of being understood
HEMEL HEMPSTEAD, United Kingdom – 5 Sept. 2023 – Boston Scientific (NYSE: BSX) today revealed survey results of 2,000 people living with chronic pain in the United Kingdom (UK) that unveiled...
May 18, 2023Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in ClonmelTaoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel CLONMEL, IRELAND (19 May 2023) - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million...
-
Nov 29, 2022
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...
-
Nov 8, 2022Dual-stage algorithm detects and verifies potential heart arrhythmias to help increase clinical efficiency
LONDON, November 8, 2022 – Boston Scientific Corporation (NYSE: BSX) today announced the European launch of the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a long-term diagnostic device...
Apr 14, 2022Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming yearsBOSTON SCIENTIFIC ANNOUNCES €100M INVESTMENT IN GALWAY CAMPUS Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years GALWAY, IRELAND (14 April...
-
Apr 4, 2022More UK patients with Benign Prostatic Enlargement (BPE) should now have improved access to these treatments thanks to inclusion in medtech funding pathway
HEMEL HEMPSTEAD, UK., Mon 4 April, 2022– Boston Scientific Corporation (NYSE: BSX) is pleased to announce the inclusion of two innovative devices in this year’s NHS MedTech Funding Mandate...
-
Feb 15, 2022
MARLBOROUGH, Mass., February 15, 2022– Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced...
-
Dec 8, 2021Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
Sep 29, 2021Investment earmarked for new technology capabilities and jobs growthCORK (29 September 2021) – Boston Scientific Corporation (NYSE: BSX) today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
-
Sep 2, 2021Fast-Acting Sub-perception Therapy (FAST) clinically proven to demonstrate significant and sustained pain relief within minutes
MARLBOROUGH, Mass., September 2, 2021 – Boston Scientific (NYSE: BSX) today announced the European launch of FAST Therapy for its WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems. The new...
-
Aug 29, 2021
MARLBOROUGH, Mass., DATE, 2021– Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops...
-
Aug 4, 2021Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System Study is first to compare interventional therapy in combination with anticoagulation to...
-
Jun 24, 2021Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...
Jun 9, 2021The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing Radiation for Prostate CancerBoston Scientific Initiates European Launch of Spaceoar Vue™ Hydrogel The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing...
-
May 25, 2021Company to begin limited market release in Europe in June
Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25 2021 -- Boston Scientific...
-
May 18, 2021
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System MARLBOROUGH, Mass., May 18, 2021 –
-
Feb 26, 2021
LONDON, UK (26 February 2021) The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of TheraSphere™ Y-90 Glass Microspheres for the treatment of...
-
Sep 30, 2020SCS portfolio features full-body MRI conditional devices that combine therapy optionsfor personalized pain relief
MARLBOROUGH, Mass., September 30, 2020 – Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The...
-
Sep 28, 2020Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior Version
Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...
-
Sep 10, 2020
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...
-
Jan 22, 2020
Paris, France., (22 January, 2020) Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark and initiated a limited market release of the EXALT™ Model D Single-Use...
-
Oct 17, 2019Boston Scientific Announces CE Mark Approval of the Vercise™ Neural Navigator 3 Programming Software
Boston Scientific Corporation announced the CE Mark approval of the Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming software - the first system that integrates...
Sep 23, 2019Arnhem (The Netherlands), 23 September 2019 - Awareness of prostate health is alarmingly low in men over 50, a new survey1 commissioned by the European Association of Urology (EAU) has revealed,...
-
Jan 31, 2019System offers multiple non-drug therapies for people with chronic pain
Boston today announced the launch of the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System in Europe. The Spectra WaveWriter SCS System is the first and only system for the treatment of...
-
Jan 22, 2019
Boston Scientific today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically...
-
Sep 26, 2018
Boston Scientific Corporation today announced the launch of the GUIDE™ XT System for visualization of Deep Brain Stimulation (DBS) in Europe. The GUIDE XT System is the first DBS visualization...
-
Sep 24, 2018
Arnhem (The Netherlands), 24 September 2018 - Public awareness of urological conditions is alarmingly low throughout Europe. Results of a new international survey of more than 2,500 respondents in...
-
Sep 17, 2018Global BT registry data presented at European Respiratory Society Conference
Boston Scientific today announced positive results from the Bronchial Thermoplasty Global Registry (BTGR) observing patients with severe asthma undergoing treatment with bronchial thermoplasty...
-
Sep 10, 2018Advanced Sealing Technology May Reduce Rates of Paravalvular Leakage
A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2™ Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system,...
May 29, 2018The HeartLogic™ Diagnostic is the first and only heart failure diagnostic tool proven to detect 70% of heart failure events several weeks in advance, potentially reducing further hospitalisation for patients with heart failureBoston Scientific Europe today announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart...
-
Mar 28, 2018U.K. Court Affirms that Edwards Lifesciences Infringes Boston Scientific Patent
Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 16, 2017Acquisition Expands Company’s Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
Apr 25, 2017Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
The prospective, randomized, controlled trial, comparing the Ranger DCB to uncoated PTA balloons, included 105 patients with femoropopliteal lesions, at ten centers in Europe. Results demonstrate...
Mar 16, 2017Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savingsToday, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...
-
Feb 6, 2017
Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...
-
Oct 13, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...
-
Jun 14, 2016Studies show that treatment is less costly and has lower hospital re-admissions
Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...
-
May 19, 2016Final, 5-year results from the EVOLVE Trial evaluating the Boston Scientific (NYSE: BSX) SYNERGY Stent support long-term safety and efficacy for the treatment of patients with de novo coronary artery disease.
The final 5 year results of the EVOLVE Trial reinforce earlier findings of sustained performance of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System, with no stent thrombosis (ST), a...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Outcomes from this post market study of more than 1,000 patients demonstrate the safety and efficacy of transcatheter aortic valve implantation (TAVI) with the LOTUS™ Valve in routine clinical practice.
Results from the RESPOND Study evaluating the Boston Scientific (NYSE: BSX) LOTUS™ Valve demonstrated excellent outcomes of key safety and efficacy endpoints through 30 days post implant...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 13, 2016WATCHMAN™ LAAC Device EWOLUTION Real-World Outcomes to be Featured as Late Breaking Clinical Trial
Boston Scientific (NYSE: BSX) today announced its schedule of key data, that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...
May 3, 2016To mark World Asthma Day, Boston Scientific continues with our commitment to raise awareness of the devastating impact severe asthma can have. Severe asthma isn’t just ‘really bad asthma’,...
-
May 2, 2016“Despite my disease, I want to set things in motion, starting with myself!”
On average about 48 kilometers – that is the distance that Tony Seidl will cycle every day during his eleven day tour from Altoetting, Germany to Padua, Italy. For most people this would already...
-
Apr 20, 2016European Approval Granted for Third-Generation System and All Previously Implanted, Second-Generation Systems
Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...
-
Apr 11, 2016
In recognition of James Parkinson's birthday, April 11th is celebrated globally as World Parkinson's Day. Parkinson’s disease (PD) is a chronic progressive neurological disorder which affects...
-
Feb 22, 2016First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and Asia
Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...
Jan 12, 2016Single-Use System for stone removal eliminates maintenance, reprocessing and sterilizationBoston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVueTM Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...
-
Dec 11, 2015
Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Sep 28, 2015A media briefing with a difference: join us for this interactive session on severe asthma. Hear from Europe’s leading experts in asthma and visit our information stations to bring the story to life.
September 28, 2015, 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (15 minutes from the ERS Congress Venue, the Amsterdam RAI Exhibition and Convention Centre) Agenda 18:30 Welcome and scene...
-
Sep 28, 2015Work, social and family life all affected by severe asthma, many people report feelings of anxiety, depression and isolation as well
Boston Scientific today revealed results of a comprehensive survey which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a...
-
Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
-
Sep 26, 2015
Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...
-
Sep 10, 2015System includes first directional lead with current steering and expanded programming flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
-
Aug 31, 2015
Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...
-
Aug 24, 2015
Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...
-
Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase the American Medical Systems (AMS)...
-
Jul 22, 2015
First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new...
-
Jun 23, 2015The new generation of subcutaneous defibrillators selected as most innovative in the field of cardiac electrophysiology.
MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...
-
Jun 22, 2015
Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...
-
Jun 10, 2015Please join us for a Boston Scientific press event. Protection from sudden cardiac death, just under the skin: the EMBLEM™ Subcutaneous ICD System
SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...
-
Jun 4, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord...
-
May 20, 2015
Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year.
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling Results
In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
-
Apr 27, 2015
Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
-
Mar 19, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Aug 30, 2014
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Jul 11, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman. DISCLAIMER: Please be...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 21, 2014
Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred Further validating its advanced transcatheter aortic valve implantation (TAVI)...